Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study

Nature Clinical Practice Oncology volume 3, pages 536–537 (2006)Cite this article

boxed-textCabrespine A et al. (2006) Randomized phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Urology 67: 354–359

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512

    Article  CAS  Google Scholar 

  2. Petrylak DP et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520

    Article  CAS  Google Scholar 

  3. Berry WR et al. (2004) Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer 3: 104–111

    Article  CAS  Google Scholar 

  4. Kelly WK et al. (2001) Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19: 44–53

    Article  CAS  Google Scholar 

  5. Smith DC et al. (2003) Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98: 269–276

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Memorial Sloan–Kettering Cancer Center,

    Michael J Morris

  2. medicine at the Sanford Weil Medical College of Cornell University, New York, NY, USA

    Michael J Morris

Authors
  1. Michael J Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J Morris.

Ethics declarations

Competing interests

MJ Morris is a consultant for Sanofi-Aventis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, M. Paclitaxel and carboplatin versus mitoxantrone: lessons of an underpowered study. Nat Rev Clin Oncol 3, 536–537 (2006). https://doi.org/10.1038/ncponc0593

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0593

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing